STANDARD BIOTOOLS INC (LAB) Stock Price & Overview

NASDAQ:LAB • US34385P1084

Current stock price

0.9079 USD
-0.01 (-1.13%)
At close:
0.9079 USD
0 (0%)
After Hours:

The current stock price of LAB is 0.9079 USD. Today LAB is down by -1.13%. In the past month the price decreased by -10.99%. In the past year, price decreased by -15.15%.

LAB Key Statistics

52-Week Range0.88 - 1.72
Current LAB stock price positioned within its 52-week range.
1-Month Range0.88 - 1.04
Current LAB stock price positioned within its 1-month range.
Market Cap
349.151M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.20
Dividend Yield
N/A

LAB Stock Performance

Today
-1.13%
1 Week
-5.23%
1 Month
-10.99%
3 Months
-28.51%
Longer-term
6 Months -32.25%
1 Year -15.15%
2 Years -63.39%
3 Years -46.59%
5 Years N/A
10 Years N/A

LAB Stock Chart

STANDARD BIOTOOLS INC / LAB Daily stock chart

LAB Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to LAB. When comparing the yearly performance of all stocks, LAB is a bad performer in the overall market: 86.3% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

LAB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LAB. While LAB seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LAB Earnings

On February 24, 2026 LAB reported an EPS of 0.05 and a revenue of 23.80M. The company beat EPS expectations (170.72% surprise) and beat revenue expectations (27.33% surprise).

Next Earnings DateMay 4, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.05
Revenue Reported23.795M
EPS Surprise 170.72%
Revenue Surprise 27.33%

LAB Forecast & Estimates

7 analysts have analysed LAB and the average price target is 1.58 USD. This implies a price increase of 74.14% is expected in the next year compared to the current price of 0.9079.

For the next year, analysts expect an EPS growth of 19.2% and a revenue growth 1.44% for LAB


Analysts
Analysts77.14
Price Target1.58 (74.03%)
EPS Next Y19.2%
Revenue Next Year1.44%

LAB Groups

Sector & Classification

LAB Financial Highlights

Over the last trailing twelve months LAB reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 63.64% compared to the year before.


Income Statements
Revenue(TTM)105.90M
Net Income(TTM)-74.90M
Industry RankSector Rank
PM (TTM) N/A
ROA -13.19%
ROE -17.65%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%155.56%
Sales Q2Q%-49.07%
EPS 1Y (TTM)63.64%
Revenue 1Y (TTM)-39.29%

LAB Ownership

Ownership
Inst Owners78.49%
Shares384.57M
Float374.76M
Ins Owners2.39%
Short Float %2.21%
Short Ratio4.4

About LAB

Company Profile

LAB logo image Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in Boston, Massachusetts. The company went IPO on 2011-02-10. The firm develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The firm's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.

Company Info

IPO: 2011-02-10

STANDARD BIOTOOLS INC

50 MILK STREET, 10TH FLOOR

Boston MASSACHUSETTS US

Employees: 818

LAB Company Website

LAB Investor Relations

Phone: 16502666000

STANDARD BIOTOOLS INC / LAB FAQ

What does STANDARD BIOTOOLS INC do?

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in Boston, Massachusetts. The company went IPO on 2011-02-10. The firm develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The firm's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.


What is the stock price of STANDARD BIOTOOLS INC today?

The current stock price of LAB is 0.9079 USD. The price decreased by -1.13% in the last trading session.


Does LAB stock pay dividends?

LAB does not pay a dividend.


What is the ChartMill technical and fundamental rating of LAB stock?

LAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the employee count for LAB stock?

STANDARD BIOTOOLS INC (LAB) currently has 818 employees.


Can you provide the upcoming earnings date for STANDARD BIOTOOLS INC?

STANDARD BIOTOOLS INC (LAB) will report earnings on 2026-05-04.


Who owns STANDARD BIOTOOLS INC?

You can find the ownership structure of STANDARD BIOTOOLS INC (LAB) on the Ownership tab.